Clinical Development Pharma Companies Regulations 
Drug Target Review
MAY 26, 2025
With a particular focus on biologics, cell, and gene therapies, Galbraiths work is centred on equipping drug developers with the tools, insights, and support needed to advance their therapies from concept to clinic. “Regulators are also much more interested in the manufacturing process, especially when it comes to stability.”
Metabolite Tales Blog
DECEMBER 19, 2023
Metabolite Bioanalysis in Drug Development: Recommendations from the IQ Consortium Metabolite Bioanalysis Working Group A Metabolite Bioanalysis Working Group comprised of experts from 14 different pharma companies have proposed recommendations around best practice in metabolite bioanalysis during drug development.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
DECEMBER 17, 2020
Cadavid will be responsible for the strategy, direction and execution of the company’s clinical development programs. Prior to Fulcrum, Cadavid held several leadership positions at Biogen, including Senior Medical Director of the multiple sclerosis clinical development group. Immune Regulation – U.K.-based
Altus Drug Development
JUNE 28, 2022
What R&D efforts are needed to develop value-added medicines? A considerable R&D investment is required to optimize health systems and develop new drugs and therapeutic devices. A clinical development program may be required for the proper health technology assessment of value-added medicines.
The Pharma Data
NOVEMBER 5, 2020
The demand for an effective drug for nail fungus is high and MOB-015 can achieve a unique market position through its high antifungal effect,” says Anna Ljung, CEO of Moberg Pharma. The information was submitted for publication, through the agency of the contact persons set out above, at 8.00 CET on November 6, 2020.
The Pharma Data
DECEMBER 16, 2020
Recombinant monoclonal antibodies are designed to enhance the immune system’s ability to regulate cell functions. The company currently plans to include more than 4,000 participants in additional trials, which it believes could support an initial regulatory approval as soon as the fourth quarter of 2021. government in September.
Expert insights. Personalized for you.
Let's personalize your content